The following excerpt is from the company's SEC filing.



PDL BioPharma to Hold Annual Meeting of Stockholders on June 2, 2016

INCLINE VILLAGE, NV, March 1, 2016 – PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, June 2, 2016, at 10:00 a.m. Pacific Time for all stockholders of record on April 8, 2016. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.

About PDL BioPharma

PDL manages a portfolio of patents and royalty assets, consi sting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has committed over $1 billion and funded approximately $937 million in these investments to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on acquiring new income generating assets, the management of its intellectual property and income generating assets, and maximizing value for its stockholders.

The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.

For more information, please visit

PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

The above information was disclosed in a filing to the SEC. To see the filing, click here. PDL BioPharma next reports earnings on May 04, 2016.

To receive a free e-mail notification whenever PDL BioPharma makes a similar move, sign up!

Other recent filings from the company include the following:

Regulation FD - Feb. 21, 2018
Pdl Biopharma Terminates Interest In Pursuing Acquisition Of Neos - Feb. 20, 2018
Renaissance Technologies LLC just provided an update on share ownership of PDL BioPharma - Feb. 14, 2018
STATE STREET CORPORATION just provided an update on share ownership of PDL BioPharma - Feb. 14, 2018
The Vanguard Group just provided an update on share ownership of PDL BioPharma - Feb. 9, 2018

Auto Refresh